This WHO guideline provides updated, evidence-informed recommendations for clinical management of HIV within a public health framework. Released in late 2025, the guidance updates antiretroviral therapy standards, strengthens interventions to prevent mother-to-child (vertical) HIV transmission, and enhances strategies to prevent tuberculosis (TB) among people living with HIV. It is designed to simplify HIV care, improve treatment outcomes, promote equity in access, and support global efforts to end AIDS as a public health threat by 2030.
Key Insights:
• Reinforces use of dolutegravir-based regimens as preferred first-line and subsequent treatment options due to strong evidence of efficacy and tolerability.
• Introduces updated guidance on new antiretroviral drugs and treatment options, including long-acting injectable therapies for selected populations.
• Revises prophylaxis and care recommendations to reduce vertical HIV transmission and integrates shortened TB preventive treatment regimens for people living with HIV.
• Aims to streamline clinical decision-making with simplified care protocols that support equitable, scalable, and cost-effective HIV services worldwide.
